title: Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines.
abstract: N-[2-[(4-Hydroxyphenyl)amino]-3-pyridyl]-4-methoxybenzenesulfonamide+ ++ (E7010) is a novel sulfonamide antimitotic agent, which is active against mouse and human tumors. E7010 binds to beta-tubulin and inhibits polymerization of microtubules. In order to clarify the mechanisms of E7010-resistance, two murine leukemic P388 subclones resistant to E7010, 0.5r-D and 4.0r-M, were characterized. The two clones showed approximately 10- and 100-fold resistance to E7010-induced growth-inhibitory effects, respectively, compared with the parental cells in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. These cell lines showed no cross-resistance to other anticancer agents such as taxanes, vinca alkaloids, mitomycin C, cisplatin and irinotecan hydrochloride (CPT-11). Increased alpha- and beta-tubulin protein and mRNA levels were observed in 0.5r-D and 4.0r-M cells as compared with the parental cells. We examined the isotype-specific expression of beta-tubulin in these E7010-resistant cells by a competitive reverse transcription-polymerase chain reaction method. Although a 50% increase in beta 5 isotype mRNA levels was observed in 4.0r-M cells, the levels of beta 3 isotype message in the two resistant clones were approximately 50% less than the parental cells. To elucidate the binding properties of E7010 with beta-tubulin isotypes, we prepared isotype-specific fusion proteins of beta-tubulins. Direct photoaffinity labeling of the isotype-specific fusion proteins with [14C]E7010 revealed that E7010 preferentially binds to the beta 3 isotype rather than beta 2, beta 4, and beta 5 isotype proteins. Therefore, altered expression of beta-tubulin isotypes, especially beta 3 isotype, to which E7010 binds with high affinity, may account for the decreased sensitivity of these resistant clones to E7010.
authors.affiliation: Pharmacology Division, National Cancer Center Hospital, Tokyo.
authors.forename: Y
authors.initials: Y
authors.lastname: Iwamoto
authors.forename: K
authors.initials: K
authors.lastname: Nishio
authors.forename: H
authors.initials: H
authors.lastname: Fukumoto
authors.forename: K
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: M
authors.initials: M
authors.lastname: Yamakido
authors.forename: N
authors.initials: N
authors.lastname: Saijo
mesh_terms: D000627:Aminophenols / Q000378:metabolism*; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D015870:Gene Expression; D006801:Humans; D007163:Immunosorbent Techniques; D007941:Leukemia P388; D051379:Mice; D019920:Photoaffinity Labels; D012333:RNA, Messenger / Q000378:metabolism; D011993:Recombinant Fusion Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000378:metabolism*; D014404:Tubulin / Q000235:genetics / Q000378:metabolism*; D000096926:Benzenesulfonamides
chemical_list: D000627:Aminophenols; D000970:Antineoplastic Agents; D019920:Photoaffinity Labels; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D013449:Sulfonamides; D014404:Tubulin; C079199:E 7010; D000096926:Benzenesulfonamides